Biospecimen Procurement Market by Therapeutic Area (Oncological Disorders and Other Disorders), Type of Biospecimen for Oncological Studies (FFPE Tissue, Frozen Tissue, Plasma / Serum and Other Biospecimens), Type of Biospecimen for Non-Oncological Studies (Blood Products, Human Tissue and Other Biospecimens), Key Geographical Regions (North America (US and Canada), Europe (Germany, France, Italy, UK, Spain and Other European Countries) and Asia Pacific (China, India, Japan and other Asia-Countries and Rest of the World)): Industry Trends and Global Forecasts, 2021-2030
The biospecimen procurement market is expected to reach USD 52 million in 2021 and anticipated to grow at a CAGR of 16% during the forecast period 2021-2035.
Biomedical research follows a cyclical path, characterized by a diverse array of experiments focused on comprehending diseases and crafting treatments. Central to this progression are biospecimens, critical elements utilized in drug development, clinical trials, and epidemiological investigations. In the domain of precision medicine, biospecimens act as a pivotal link connecting a patient's biology to the customization of therapies. However, acquiring, preserving, and thoroughly analyzing high-quality biospecimens pose persistent challenges in the pharmaceutical industry. These hurdles often result in research delays and elongated timelines for drug approvals. Ensuring reliable and efficient tracking of biospecimens demands unique identifiers, sophisticated data management systems, and stringent quality control measures. Furthermore, the ethical and legal complexities surrounding biobanking remain constantly evolving, with ongoing development of regulations governing the maintenance of human biospecimens.
Technological advancements in biospecimen research over recent decades have significantly improved the acquisition of superior biospecimens tailored for molecular research. Notably, novel and refined methodologies for obtaining, processing, and storing biospecimens have emerged in the industry. There is a noticeable trend in the pharmaceutical industry toward outsourcing bioanalytical services. This strategic shift aims to capitalize on cost-effective methods and address existing capacity constraints. This shift is evident through increased collaboration activities aimed at expanding the capabilities of service providers. These partnerships strive to offer specialized services in biospecimen procurement and analysis. Based on prevailing patterns, it is foreseeable that more developers and innovators will rely on contract research organizations to navigate existing challenges and drive innovation in drug development. Consequently, this trend is expected to create more opportunities for service providers in the anticipated future.
Report Coverage
Biomedical research follows a cyclical path, characterized by a diverse array of experiments focused on comprehending diseases and crafting treatments. Central to this progression are biospecimens, critical elements utilized in drug development, clinical trials, and epidemiological investigations. In the domain of precision medicine, biospecimens act as a pivotal link connecting a patient's biology to the customization of therapies. However, acquiring, preserving, and thoroughly analyzing high-quality biospecimens pose persistent challenges in the pharmaceutical industry. These hurdles often result in research delays and elongated timelines for drug approvals. Ensuring reliable and efficient tracking of biospecimens demands unique identifiers, sophisticated data management systems, and stringent quality control measures. Furthermore, the ethical and legal complexities surrounding biobanking remain constantly evolving, with ongoing development of regulations governing the maintenance of human biospecimens.
Technological advancements in biospecimen research over recent decades have significantly improved the acquisition of superior biospecimens tailored for molecular research. Notably, novel and refined methodologies for obtaining, processing, and storing biospecimens have emerged in the industry. There is a noticeable trend in the pharmaceutical industry toward outsourcing bioanalytical services. This strategic shift aims to capitalize on cost-effective methods and address existing capacity constraints. This shift is evident through increased collaboration activities aimed at expanding the capabilities of service providers. These partnerships strive to offer specialized services in biospecimen procurement and analysis. Based on prevailing patterns, it is foreseeable that more developers and innovators will rely on contract research organizations to navigate existing challenges and drive innovation in drug development. Consequently, this trend is expected to create more opportunities for service providers in the anticipated future.
Report Coverage
- The report conducts an analysis of the biospecimen procurement market, examining it through various lenses such as therapeutic area, biospecimen types, geographical regions, and non-oncological study specimens
- It evaluates the market growth influencers—factors like drivers, restraints, opportunities, and challenges—assessing their impact on the industry.
- The report delves into potential advantages and barriers within the market landscape, providing insights into the competitive dynamics among the leading market players.
- Revenue projections for market segments are forecasted concerning four major regions, offering a comprehensive outlook on market growth.
- An extensive assessment of companies providing biospecimen-related research services encompasses multiple crucial parameters, including establishment year, company size, headquarters location, and the range of biospecimens and analytical services offered across various regions.
- Competitive analysis involves evaluating biospecimen contract research service providers' portfolio strength, service capabilities, and supplier strengths across different regions.
- Profiles of major players in North America, Europe, and Asia-Pacific encompass company overviews, offered services, analytical capabilities, recent developments, and future outlooks in the biospecimen research domain.
- Examination of biospecimen procurement partnerships post-2015 includes deals focused on biospecimen services, mergers/acquisitions, agreements, alliances, distribution deals, joint ventures, and other collaboration agreements.
- A comprehensive case study of commercial biobanks involves parameters like establishment year, company size, services offered, handled biospecimens, therapeutic areas, and competitiveness based on their biorepository offerings.
- Further analysis of biospecimen contract research service providers is presented through schematic representations, including grid analysis, breakdown by therapeutic area and active players, assessment of company size related to therapeutic areas, and a world map indicating regional distribution based on biorepository locations.
- BioChain Institute
- BioIVT
- Creative Bioarray
- Discovery Life Sciences
- Infinity BiologiX
- Precision for Medicine
- PrecisionMed
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Biospecimen
3.3. Importance of Biospecimen in Drug Discovery and Research
3.4. Factors Affecting the Quality of Biospecimen
3.5. Biospecimen Management
3.6. Regulatory Guidelines
3.7. Outsourcing in Biospecimen Research
3.7.1. Role of Contract Research Organizations in Biospecimen Procurement
3.7.2. Types of Services Offered by Contract Research Organizations
3.8. Future Perspective
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biospecimen Research Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Blood Product(s) Offered
4.2.5. Analysis by Type of Human Tissue(s) Offered
4.2.6. Analysis by Type of Biofluid(s) and Other Biospecimen(s) Offered
4.2.7. Analysis of Type of Analytical Service(s) Offered
4.2.8. Analysis by Type of Sample(s) Offered
4.2.9. Analysis of Accreditation(s) Received
4.2.10. Analysis by Geographical Reach
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Key Parameters
5.4. Competitiveness Analysis: Biospecimen Research Service Providers with Biorepositories
5.4.1. Companies Offering Biospecimen Research Services in North America
5.4.2. Companies Offering Biospecimen Research Services in Europe and Asia-Pacific
5.5. Competitiveness Analysis: Biospecimen Research Service Providers without Biorepositories
5.5.1. Companies Offering Biospecimen Research Services in North America
5.5.2. Companies Offering Biospecimen Research Services in Europe
6. BIOSPECIMEN SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. BioChain Institute
6.2.1. Company Overview
6.2.2. Biospecimen Related Service Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. BioIVT
6.3.1. Company Overview
6.3.2. Biospecimen Related Service Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Creative Bioarray
6.4.1. Company Overview
6.4.2. Biospecimen Related Service Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Discovery Life Sciences
6.5.1. Company Overview
6.5.2. Biospecimen Related Service Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Infinity BiologiX
6.6.1. Company Overview
6.6.2. Biospecimen Related Service Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Precision for Medicine
6.7.1. Company Overview
6.7.2. Biospecimen Related Service Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. PrecisionMed
6.8.1. Company Overview
6.8.2. Biospecimen Related Service Portfolio
6.8.3. Recent Developments and Future Outlook
7. BIOSPECIMEN SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. Medicover
7.2.1. Company Overview
7.2.2. Biospecimen Related Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. National BioService
7.3.1. Company Overview
7.3.2. Biospecimen Related Service Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. REPROCELL
7.4.1. Company Overview
7.4.2. Biospecimen Related Service Portfolio
7.4.3. Recent Developments and Future Outlook
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Biospecimen Research Services: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Collaborator
8.3.4. Analysis by Type of Service(s) Offered
8.3.5. Analysis by Type of Biospecimen(s) Handled
8.3.6. Analysis by Therapeutic Area
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.4. Geographical Analysis
8.4.1. Intercontinental and intracontinental Agreements
9. CASE STUDY: MARKET LANDSCAPE OF COMMERCIAL BIOBANKS
9.1. Chapter Overview
9.2. Commercial Biobanks: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters
9.2.4. Analysis by Types of Service(s) Offered
9.2.5. Analysis by Types of Biospecimen(s) Handled
9.2.6. Analysis by Therapeutic Area
9.3. Company Competitiveness Analysis
9.3.1. Methodology and Key Parameters
9.3.2. Competitiveness Analysis: Commercial Biobanks with Biorepositories
9.3.3. Competitiveness Analysis: Commercial Biobanks without Biorepositories
10. KEY INSIGHTS
10.1. Chapter Overview
10.2 Grid Analysis: Analysis by Year of Establishment and Type of Analytical Service(s) Offered
10.3. Analysis by Company Size and Therapeutic Area
10.4 Most Active Players: Analysis by Therapeutic Area and
10.5. World Map Representation: Analysis by Location of In-House Biorepositories
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall Biospecimen Research Services Market, 2021-2030
11.3.1. Biospecimen Research Services Market, 2021-2030: Distribution by Type of Biospecimen
11.3.2. Biospecimen Research Services Market, 2021-2030: Distribution by Therapeutic Area
11.3.3. Biospecimen Research Services Market, 2021-2030: Distribution by Key Geographical Regions
11.3.3.1. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Countries
11.3.3.2. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Type of Biospecimen
11.3.3.3. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Therapeutic Area
11.3.3.4. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Countries
11.3.3.5. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Type of Biospecimen
11.3.3.6. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Therapeutic Area
11.3.3.4. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Countries
11.3.3.5. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biospecimen
11.3.3.6. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area
12. CONCLUSION
12.1. Chapter Overview
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. BioSpecimen Solutions
13.2.1. Overview of Company / Organization
13.2.2. Interview Transcript: Ramachandra Rao, Managing Director and Business Development Head
13.3. National BioService
13.3.1. Overview of Company / Organization
13.3.2. Interview Transcript: Oleg Granstrem, Director of Business Development
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Biospecimen
3.3. Importance of Biospecimen in Drug Discovery and Research
3.4. Factors Affecting the Quality of Biospecimen
3.5. Biospecimen Management
3.6. Regulatory Guidelines
3.7. Outsourcing in Biospecimen Research
3.7.1. Role of Contract Research Organizations in Biospecimen Procurement
3.7.2. Types of Services Offered by Contract Research Organizations
3.8. Future Perspective
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biospecimen Research Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Blood Product(s) Offered
4.2.5. Analysis by Type of Human Tissue(s) Offered
4.2.6. Analysis by Type of Biofluid(s) and Other Biospecimen(s) Offered
4.2.7. Analysis of Type of Analytical Service(s) Offered
4.2.8. Analysis by Type of Sample(s) Offered
4.2.9. Analysis of Accreditation(s) Received
4.2.10. Analysis by Geographical Reach
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Key Parameters
5.4. Competitiveness Analysis: Biospecimen Research Service Providers with Biorepositories
5.4.1. Companies Offering Biospecimen Research Services in North America
5.4.2. Companies Offering Biospecimen Research Services in Europe and Asia-Pacific
5.5. Competitiveness Analysis: Biospecimen Research Service Providers without Biorepositories
5.5.1. Companies Offering Biospecimen Research Services in North America
5.5.2. Companies Offering Biospecimen Research Services in Europe
6. BIOSPECIMEN SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. BioChain Institute
6.2.1. Company Overview
6.2.2. Biospecimen Related Service Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. BioIVT
6.3.1. Company Overview
6.3.2. Biospecimen Related Service Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Creative Bioarray
6.4.1. Company Overview
6.4.2. Biospecimen Related Service Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Discovery Life Sciences
6.5.1. Company Overview
6.5.2. Biospecimen Related Service Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Infinity BiologiX
6.6.1. Company Overview
6.6.2. Biospecimen Related Service Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Precision for Medicine
6.7.1. Company Overview
6.7.2. Biospecimen Related Service Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. PrecisionMed
6.8.1. Company Overview
6.8.2. Biospecimen Related Service Portfolio
6.8.3. Recent Developments and Future Outlook
7. BIOSPECIMEN SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. Medicover
7.2.1. Company Overview
7.2.2. Biospecimen Related Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. National BioService
7.3.1. Company Overview
7.3.2. Biospecimen Related Service Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. REPROCELL
7.4.1. Company Overview
7.4.2. Biospecimen Related Service Portfolio
7.4.3. Recent Developments and Future Outlook
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Biospecimen Research Services: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Collaborator
8.3.4. Analysis by Type of Service(s) Offered
8.3.5. Analysis by Type of Biospecimen(s) Handled
8.3.6. Analysis by Therapeutic Area
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.4. Geographical Analysis
8.4.1. Intercontinental and intracontinental Agreements
9. CASE STUDY: MARKET LANDSCAPE OF COMMERCIAL BIOBANKS
9.1. Chapter Overview
9.2. Commercial Biobanks: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters
9.2.4. Analysis by Types of Service(s) Offered
9.2.5. Analysis by Types of Biospecimen(s) Handled
9.2.6. Analysis by Therapeutic Area
9.3. Company Competitiveness Analysis
9.3.1. Methodology and Key Parameters
9.3.2. Competitiveness Analysis: Commercial Biobanks with Biorepositories
9.3.3. Competitiveness Analysis: Commercial Biobanks without Biorepositories
10. KEY INSIGHTS
10.1. Chapter Overview
10.2 Grid Analysis: Analysis by Year of Establishment and Type of Analytical Service(s) Offered
10.3. Analysis by Company Size and Therapeutic Area
10.4 Most Active Players: Analysis by Therapeutic Area and
10.5. World Map Representation: Analysis by Location of In-House Biorepositories
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall Biospecimen Research Services Market, 2021-2030
11.3.1. Biospecimen Research Services Market, 2021-2030: Distribution by Type of Biospecimen
11.3.2. Biospecimen Research Services Market, 2021-2030: Distribution by Therapeutic Area
11.3.3. Biospecimen Research Services Market, 2021-2030: Distribution by Key Geographical Regions
11.3.3.1. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Countries
11.3.3.2. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Type of Biospecimen
11.3.3.3. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Therapeutic Area
11.3.3.4. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Countries
11.3.3.5. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Type of Biospecimen
11.3.3.6. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Therapeutic Area
11.3.3.4. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Countries
11.3.3.5. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biospecimen
11.3.3.6. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area
12. CONCLUSION
12.1. Chapter Overview
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. BioSpecimen Solutions
13.2.1. Overview of Company / Organization
13.2.2. Interview Transcript: Ramachandra Rao, Managing Director and Business Development Head
13.3. National BioService
13.3.1. Overview of Company / Organization
13.3.2. Interview Transcript: Oleg Granstrem, Director of Business Development
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
